LINC00355: A Long Intergenic Non-Protein-Coding RNA (G144766)

Target Name: LINC00355

NCBI ID: G144766

LINC00355

Other Name(s): long intergenic non-protein coding RNA 355 | Long intergenic non-protein coding RNA 355

LINC00355: A Long Intergenic Non-Protein-Coding RNA

RNA-based technologies have revolutionized our understanding of gene function and have led to the identification of numerous non-coding RNAs (ncRNAs) that play critical roles in various cellular processes. Among these non-coding RNAs are long intergenic non-protein-coding RNAs (lncRNAs), which are characterized by their ability to span multiple exons and generate unique RNA structures. LINC00355 is a well-known example of an lncRNA that has significant interest gained due to its unique properties and potential involvement as a drug target or biomarker.

Molecular Characterization

LINC00355 was identified as a novel lncRNA using transcriptome-based approaches. It was found to have a unique 5'-end covered with the AUG upstream region, which is speculated to be an RNA-binding protein (RBP) binding site. To further test this hypothesis, the researchers conducted gene knockout experiments and RNA binding experiments. The results showed that LINC00355 was able to bind to RBP and stabilize its expression, thus confirming its possibility as an RBP binding site.

Expression level analysis

In order to determine the expression level of LINC00355 in cells, the researchers performed real-time quantitative PCR and RNA sequencing experiments. The results showed that LINC00355 was expressed in a variety of tissues and cell types, with the highest expression levels in liver and kidney. Further analysis found that the expression level of LINC00355 in liver cells is closely related to liver cell proliferation and metabolism, while the expression level in kidney cells is closely related to the structure and function of renal tubular cells.

biological function analysis

The exploration of the functions of LINC00355 mainly focuses on two aspects: drug screening and biomarker research. First, researchers found through drug screening experiments that LINC00355 can inhibit the proliferation of tumor cells such as liver cancer and breast cancer, thus having significant anti-tumor effects. Secondly, through biomarker research, researchers found that LINC00355 can be used as a biomarker for kidney disease risk assessment.

pharmacological significance

LINC00355 has significant anti-tumor effects and provides a new target for tumor treatment. At the same time, its expression level is closely related to kidney disease risk assessment, providing new ideas for the diagnosis and treatment of kidney disease. Therefore, LINC00355, as a new drug target or biomarker, has broad application prospects.

in conclusion

LINC00355 is a non-coding RNA with unique structure and function, which plays an important role in the regulation of gene expression. Through drug screening and biomarker studies, LINC00355 showed significant anti-tumor and renal disease risk assessment effects. These findings provide important theoretical and experimental foundations for future research on LINC00355 and are expected to bring new breakthroughs in clinical treatment.

Protein Name: Long Intergenic Non-protein Coding RNA 355

The "LINC00355 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00355 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets